We have a robust drug development pipeline at various clinical and preclinical stages.
Tap the sections below to expand or download the full pipeline chart.
INVESTOR INITIATED IO
OTHER ONCOLOGY PIPELINE
Note: 1We own global rights to plinabulin in all countries except China. In China, we own a 57.97% interest in our Chinese subsidiary, Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”), which owns a 100% interest in plinabulin.